Neoadjuvant chemotherapy for extensive unilateral retinoblastoma

Bellaton, Erianna; Bertozzi, Anne Isabelle; Béhar, C; Chastagner, P.; Brisse, H.; Sainte‐Rose, Christian; Doz, François; Desjardins, Laurence

doi:10.1136/bjo.87.3.327

Cited by 75 publications

(63 citation statements)

References 12 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, in most MICs, metastatic disease is present at diagnosis in less than 10% of the cases [7,22,23]. Treatment with neoadjuvant chemotherapy, followed by secondary enucleation and adjuvant therapy is the current approach in most centers [13,40,41]. Encouraging results have been reported for the treatment of retinoblastoma that is disseminated to the orbit or the preauricular lymph nodes has resulted in disease-free survival rates over 70% [41].…”

Section: Treating Patients With Overt Extraocular Diseasementioning

confidence: 91%

Strategies to manage retinoblastoma in developing countries

Chantada

Qaddoumi

Canturk³

et al. 2010

Pediatric Blood & Cancer

128

109

View full text Add to dashboard Cite

Survival of retinoblastoma is >90% in developed countries but there are significant differences with developing countries in stage at presentation, available treatment options, family compliance, and survival. In low‐income countries (LICs), children present with advanced disease, and the reasons are socioeconomic and cultural. In middle‐income countries (MICs), survival rates are better (>70%), but there is a high prevalence of microscopically disseminated extraocular disease. Programs for eye preservation have been developed, but toxicity‐related mortality is higher. Although effective treatment of microscopically extraocular disease improved the outcome, worldwide survival will be increased only by earlier diagnosis and better treatment adherence. Pediatr Blood Cancer 2011;56:341–348. © 2010 Wiley‐Liss, Inc.

show abstract

Section: Treating Patients With Overt Extraocular Diseasementioning

confidence: 91%

Strategies to manage retinoblastoma in developing countries

Chantada

Qaddoumi

Canturk³

et al. 2010

Pediatric Blood & Cancer

128

109

View full text Add to dashboard Cite

show abstract

“…This concept was first adopted at Yale in 1979 after being evaluated in other disease sites [29][30][31]. This approach was reserved for women with medical co-morbidities and/or poor performance statuses that would significantly limit aggressive cytoreductive surgery.…”

Section: History Of Neoadjuvant Chemotherapy For Ovarian Cancermentioning

confidence: 98%

The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer

Weinberg

Rodriguez

Hurteau

2010

Journal of Surgical Oncology

View full text Add to dashboard Cite

The current management of advanced ovarian cancer consists of aggressive primary cytoreductive surgery (PCS) followed by combination platinum based chemotherapy. Recent studies have suggested that platinum-based chemotherapy may be of benefit in patients with advanced ovarian cancer prior to cytoreductive surgery (neoadjuvant chemotherapy, NACT). The concept of NACT has not been completely validated in the treatment of ovarian cancer. This review will discuss the role of NACT in patients with advanced epithelial ovarian cancer.

show abstract

“…One approach would be to try to identify them preoperatively to give neoadjuvant chemotherapy in order to downstage the disease, thereby avoiding orbital irradiation (Bellaton et al 2003). In a series of 184 initially enucleated patients with unilateral retinoblastoma at the Hospital Garrahan, glaucoma and buphthalmia were significantly associated by multivariate analysis with the occurrence of microscopically disseminated disease.…”

Section: Future Directionsmentioning

confidence: 99%

Retinoblastoma

2010

Pediatric Oncology

View full text Add to dashboard Cite

Neoadjuvant chemotherapy for extensive unilateral retinoblastoma

Cited by 75 publications

References 12 publications

Strategies to manage retinoblastoma in developing countries

Strategies to manage retinoblastoma in developing countries

The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer

Retinoblastoma

Contact Info

Product

Resources

About